quinuclidines has been researched along with Cancer of Ovary in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Arsiola, T; Böckelman, C; Butt, U; Butzow, R; Carpen, O; Connolly, DC; Cvrljevic, AN; Grönroos, TJ; Haglund, C; Huhtinen, K; Kaipio, K; Laajala, TD; Lassus, H; Pouwels, J; Ristimäki, A; Westermarck, J | 1 |
| Benbrook, DM; Bieniasz, M; Elayapillai, S; Gunderson, CC; Hunsucker, LA; Isingizwe, ZR; Kennedy, AL; Lightfoot, S; Pathuri, G; Ramraj, S; Wang, L; Zhao, YD | 1 |
| Chiwaki, F; Kato, T; Kohno, T; Kuroda, T; Makinoshima, H; Maruyama, A; Ogiwara, H; Okamoto, A; Sasaki, H; Sasaki, M; Takahashi, K; Watanabe, R; Yoshida, H | 1 |
| Alfredsson, J; Björklund, U; Bykov, VJ; Byström, S; Fransson, Å; Gullbo, J; Hallberg, A; Mohell, N; Uustalu, M; Wiman, KG | 1 |
| Callen, D; Kajiyama, H; Kikkawa, F; Mitsui, H; Nakamura, K; Niimi, K; Sekiya, R; Shibata, K; Suzuki, S; Utsumi, F; Yoshikawa, N | 1 |
| Alfredsson, J; Bajalica-Lagercrantz, S; Fransson, Å; Glaessgen, D; Mohell, N; Wiman, KG | 1 |
| Fowler, B; Klinger, E; Matta, L; McDonnell, A; Reddy, P; Voit, D; Yeh, YC | 1 |
7 other study(ies) available for quinuclidines and Cancer of Ovary
| Article | Year |
|---|---|
Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246-Sensitive Disease Subtype.
Topics: Animals; Autoantigens; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Female; Humans; Mice; NF-kappa B; Ovarian Neoplasms; Quinuclidines | 2022 |
Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Repositioning; Drug Screening Assays, Antitumor; Drug Synergism; Female; Fenbendazole; Humans; Mebendazole; Ovarian Neoplasms; Quinuclidines; Random Allocation; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2021 |
Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers.
Topics: Amino Acid Transport System y+; Animals; Antineoplastic Agents; Apoptosis; DNA-Binding Proteins; Enzyme Inhibitors; Female; Glutamate-Cysteine Ligase; Glutathione; HCT116 Cells; Humans; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Nuclear Proteins; Ovarian Neoplasms; Oxidative Stress; Quinuclidines; Transcription Factors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cells, Cultured; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Activation; Female; Gemcitabine; Glutathione; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Protein Folding; Quinuclidines; Random Allocation; Taxoids; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2015 |
PRIMA-1MET induces apoptosis through accumulation of intracellular reactive oxygen species irrespective of p53 status and chemo-sensitivity in epithelial ovarian cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Poly (ADP-Ribose) Polymerase-1; Proteolysis; Quinuclidines; Reactive Oxygen Species; Tumor Suppressor Protein p53 | 2016 |
Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer.
Topics: Antineoplastic Agents; Cell Survival; Cisplatin; Cystadenocarcinoma, Serous; DNA Damage; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Inhibitory Concentration 50; Mutation; Neoplasm Grading; Neoplasm Staging; Ovarian Neoplasms; Quinuclidines; Tumor Suppressor Protein p53 | 2016 |
Comparison of healthcare resource use between patients receiving ondansetron or palonosetron as prophylaxis for chemotherapy-induced nausea and vomiting.
Topics: Adult; Aged; Ambulatory Care; Antiemetics; Antineoplastic Agents; Boston; Cisplatin; Drug Administration Schedule; Drug Substitution; Emergency Service, Hospital; Fallopian Tube Neoplasms; Female; Health Resources; Humans; Isoquinolines; Length of Stay; Middle Aged; Nausea; Ondansetron; Ovarian Neoplasms; Palonosetron; Patient Readmission; Premedication; Quinuclidines; Risk Assessment; Risk Factors; Serotonin Antagonists; Time Factors; Treatment Outcome; Vomiting | 2011 |